Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

被引:22
作者
Wu, Fenglei [1 ]
Hu, Nan [1 ]
Li, Yu [1 ]
Bian, Baoxiang [1 ]
Xu, Guanghui [1 ]
Zheng, Yitong [1 ]
机构
[1] First People Hosp Lianyungang, Dept Oncol, Lianyungang 222002, Jiangsu, Peoples R China
关键词
Polymorphisms; Galectin-3; Non-small cell lung cancer; Chemotherapy response; CARBOHYDRATE-RECOGNITION DOMAIN; PROSTATE-CANCER; LUNG-CANCER; BINDING; PROGRESSION; EXPRESSION; EFFICACY; RISK;
D O I
10.1007/s13402-012-0075-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC). Method Three hundred twenty patients with Stage III (A+B) or IV NSCLC were enrolled. A Platinum-based chemotherapy was given to each subjects and therapeutic effect was evaluated. The two galectin-3 genetic polymorphisms, namely, galectin-3 +191 A>C and +292 A>C, were genotyped. Results The polymorphic genotypes and the allele frequency of galectin-3 +191 A>C were not significantly different between responders and non-responders to chemotherapy. For galectin-3 +292 A>C, the AA genotype and A allele distribution were significantly higher in responders than in non-responders. Logistic regression analysis showed CC genotype of galectin-3 +292 presented higher risk of being non-responders compared with the AA genotype (OR=2.96, 95 % CI: 1.55-5.47; P<0.001). The overall survival in patients with AA genotype of galectin-3 +292 were significantly longer than in those with CC genotype (25.6 vs. 19.5 months, P=0.013). The hazard ratio for CC genotype of galectin-3 +292 was 2.43 (95 % CI: 2.03-3.98, compared with AA carriers, P=0.003). Conclusion The galectin-3 genetic polymorphisms of galectin-3 +292, rather than galectin-3 +191, were associated with the chemotherapy response and prognosis of NSCLC.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 30 条
[21]   Galectin-3: A useful biomarker for differential diagnosis of brain tumors [J].
Park, Sung-Hye ;
Min, Hye Sook ;
Kim, Bomi ;
Myung, Jaekyung ;
Paek, Sun Ha .
NEUROPATHOLOGY, 2008, 28 (05) :497-506
[22]   Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope [J].
Pelletier, I ;
Sato, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (20) :17663-17670
[23]   High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy [J].
Perng, Reury-Perng ;
Yang, Chih-Hsin ;
Chen, Yuh-Min ;
Chang, Gee-Chen ;
Lin, Meng-Chih ;
Hsieh, Ruey-Kuen ;
Chu, Nei-Min ;
Lai, Ruay-Sheng ;
Su, Wu-Chou ;
Tsao, Chao-Jung ;
Hsia, Te-Chun ;
Chen, Hao-Cheng ;
Chen, Chih-Hung ;
Huang, Ming-Shyan ;
Wang, Jui-Long ;
Ho, Ming-Lin ;
Chung, Chih-Yuan ;
Yu, Chong-Jen ;
Chang, Wen-Cheng ;
Kuo, Han-Pin ;
Yu, Chih-Teng ;
Lin, Zhong-Zhe ;
Kao, Woei-Yau .
LUNG CANCER, 2008, 62 (01) :78-84
[24]   Galectin-3 Upregulation During Tumor Progression in Head and Neck Cancer [J].
Saussez, Sven ;
Decaestecker, Christine ;
Mahillon, Virginie ;
Cludts, Stephanie ;
Capouillez, Aurelie ;
Chevalier, Dominique ;
Kaltner, Herbert ;
Andre, Sabine ;
Toubeau, Gerard ;
Leroy, Xavier ;
Gabius, Hans-Joachim .
LARYNGOSCOPE, 2008, 118 (09) :1583-1590
[25]   Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras [J].
Shalom-Feuerstein, Ruby ;
Levy, Ran ;
Makovski, Victoria ;
Raz, Avraham ;
Moog, Yoel .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2008, 1783 (06) :985-993
[26]  
Tsuboi K, 2007, ANTICANCER RES, V27, P2289
[27]   Regulation of Prostate Cancer Progression by Galectin-3 [J].
Wang, Yi ;
Nangia-Makker, Pratima ;
Tait, Larry ;
Balan, Vitaly ;
Hogan, Victor ;
Pienta, Kenneth J. ;
Raz, Avraham .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (04) :1515-1523
[28]   Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients [J].
Watanabe, H ;
Yamamoto, S ;
Kunitoh, H ;
Sekine, I ;
Yamamoto, N ;
Ohe, Y ;
Tamura, T ;
Kodama, T ;
Sugimura, K ;
Saijo, N .
CANCER SCIENCE, 2003, 94 (11) :1015-1020
[29]   Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest [J].
Yoshii, T ;
Fukumori, T ;
Honjo, Y ;
Inohara, H ;
Kim, HRC ;
Raz, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (09) :6852-6857
[30]   Predictive Effects of ERCC1 and XRCC3 SNP on Efficacy of Platinum-based Chemotherapy in Advanced NSCLC Patients [J].
Zhou, Caicun ;
Ren, Shengxiang ;
Zhou, Songwen ;
Zhang, Ling ;
Su, Cunxia ;
Zhang, Zengli ;
Deng, Qinfang ;
Zhang, Jie .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) :954-960